Evaluations for In Vitro Correlates of Immunogenicity of Inactivated Influenza A H5, H7 and H9 Vaccines in Humans

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Couch, Robert B ^a   Decker, William K ^a   Utama, Budi ^a   Atmar, Robert L ^a   Niño, Diane ^a   Feng, Jing Qi ^b   Halpert, Matthew M ^a   Air, Gillian M ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; INTERLEUKIN 4;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ANTIGEN PRESENTATION; ARTICLE; BINDING AFFINITY; CELL MATURATION; CHILD; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DRUG CONFORMATION; DRUG STRUCTURE; ELECTRON MICROSCOPY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; INFANT; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; INFLUENZA VIRUS A H7N7; INFLUENZA VIRUS A H9N2; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRESCHOOL CHILD; SCHOOL CHILD; STRUCTURE ANALYSIS; T LYMPHOCYTE; VIRION; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, VIRAL; ANTIGEN PRESENTATION; BIRDS; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA A VIRUS, H7N7 SUBTYPE; INFLUENZA A VIRUS, H9N2 SUBTYPE; INFLUENZA IN BIRDS; INFLUENZA VACCINES; INFLUENZA, HUMAN; VACCINES, INACTIVATED;

EID: 84871147732     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050830     Document Type: Article

References (56)

1. Schild GC, Wood JM, Newman RW, (1975) A single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen. Bull World Health Organ 52: 223-231.
2. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M, (2006) Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354: 1343-51.
3. Leroux-Roels I, Borkowowski A, Vanwolleghem T, Dramé M, Clement F, et al. (2007) Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. The Lancet 370: 580-589.
4. Patel SM, Atmar RL, El Sahly HM, Cate TR, Keitel WA, (2010) A phase I evaluation of inactivated influenza A/H5N1 vaccine administered by the intradermal or the intramuscular route. Vaccine 28: 3025-3029.
5. Keitel WA, Campbell JD, Treanor JJ, Walter EB, Patel SM, et al. (2008) Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial. J Infect Dis 198: 1309-1316.
6. Patel SM, Atmar RL, El Sahly HM, Guo K, Hill H, et al. (2012) Direct comparison of an inactivated, subvirion influenza A virus subtype H5N1 vaccine administered by the intradermal and intramuscular routes. J Infect Dis 206: 1069-1077.
7. Nolan TM, Richmond PC, Skeljo MV, Pearce G, Hartel G, et al. (2008) Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults. Vaccine 26: 4160-4167.
8. Bernstein DI, Edwards KM, Dekker CL, Belshe R, Talbot HKB, et al. (2008) Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis 197: 667-675.
9. Bresson J-L, Perronne C, Launay O, Gerdil C, Saville M, et al. (2006) Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. The Lancet 367: 1657-1664.
10. Belshe RB, Frey SE, Graham I, Mulligan MJ, Edupuganti S, et al. (2011) Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant. J Infect Dis 203: 666-673.
11. Langley JM, Frenette L, Ferguson L, Riff D, Sheldon E, et al. (2010) Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults. J Infect Dis 201: 1644-1653.
12. Couch RB, Patel SM, Wade-Bowers CL, Niño D, (2012) A Randomized Clinical Trial of an Inactivated Avian Influenza A (H7N7) Vaccine. PLOS ONE In Press.
13. Hehme N, Engelmann H, Künzel W, Neumeier E, Sänger R, (2002) Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines. Med Microbiol Immunol 191: 203-208.
14. Atmar RL, Keitel WA, Patel SM, Katz JM, She D, et al. (2006) Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis 43: 1135-1142.
15. Keitel W, Groth N, Lattanzi M, Praus M, Hilbert AK, et al. (2010) Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial. Vaccine 28: 840-848.
16. Lin J, Zhang J, Dong X, Fang H, Chen J, et al. (2006) Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. The Lancet 368: 991-997.
17. Vajo Z, Kosa L, Visontay I, Jankovics M, Jankovics I, (2007) Inactivated whole virus vaccine influenza A (H5N1) vaccine. Emerg Infect Dis 3: 807-808.
18. Qiu Y-Z, Yin W-D, (2008) Safety and immunogenicity of Sinovac's prototype pandemic influenza H5N1 vaccines: a review on clinical trials. Influenza Other Respi Viruses 2: 227-232.
19. Ehrlich HJ, Müller M, Oh HML, Tambyah PA, Jourkhadar C, et al. (2008) A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 358: 2573-2584.
20. Keitel WA, Dekker CL, Mink C, Campbell JD, Edwards KM, et al. (2009) Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults. Vaccine 27: 6642-6648.
21. Tada Y, (2008) Characterization of a whole, inactivated influenza (H5N1) vaccine. Influenza Other Respi Viruses 2: 261-266.
22. Wu J, Fang H-H, Chen J-T, Zhou J-C, Feng Z-J, et al. (2009) Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial. Clin Infect Dis 48: 1087-1095.
23. Ikeno D, Kimachi K, Kino Y, Harada S, Yoshida K, et al. (2010) Immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1, NIBRG-14) vaccine administered by intramuscular or subcutaneous injection. Microbiol Immunol 54: 81-88.
24. Tambyah PA, Wilder-Smith A, Pavlova BG, Barrett PN, Oh HML, et al. (2012) Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine. Vaccine 30: 329-335.
25. Treanor JJ, Wilkinson BE, Masseoud F, Hu-Primmer J, Battaglia R, et al. (2001) Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19: 1732-1737.
26. Cox RJ, Madhun AS, Hauge S, Sjursen H, Major D, et al. (2009) A phase I clinical trial of a PER.C6® cell grown influenza H7 virus vaccine. Vaccine 27: 1889-1897.
27. Nicholson KG, Thompson CI, Klap JM, Wood JM, Batham S, et al. (2010) Safety and immunogenicity of whole-virus, alum-adjuvanted whole-virus, virosomal, and whole-virus intradermal influenza A/H9N2 vaccine formulations. Vaccine 28: 171-178.
28. Langley JM, Risi G, Caldwell M, Gilderman L, Berwald B, et al. (2011) Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study. J Infect Dis 203: 1729-38.
29. Nolan T, Richmond PC, Formica NT, Höschler K, Skeljo MV, et al. (2008) Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. Vaccine 26: 6383-6391.
30. Wu J, Liu S-Z, Dong S-S, Dong X-P, Zhang W-L, et al. (2010) Safety and immunogenicity of adjuvanted inactivated split-virion and whole-virion influenza A (H5N1) vaccines in children: a phase I-II randomized trial. Vaccine 28: 6221-6227.
31. Hilleman MR, Flatley FJ, Anderson SA, Luecking ML, Levinson DJ, (1958) Antibody response in volunteers to Asian influenza vaccine. JAMA 166: 1135-1140.
32. Knight V, Couch RB, Douglas RG Jr, Tauraso NM, (1971) Serologic response and natural infectious challenge of recipients of zonal ultracentrifuged influenza A2/Aichi/2/68 Vaccine. Bull WHO 45: 767-771.
33. Couch RB (2011) Lessons learned from clinical trials in 1976 and 1977 of vaccines for the newly emerged swine and Russian influenza A/H1N1 viruses. In: Rappuoli R, Del Guidice G, editors, Influenza Vaccines for the Future, ed., Birkhäuser Advances in Infectious Diseases, Heidelberg, Germany, Springer Basel, 359-371.
34. Plennevaux E, Sheldon E, Blatter M, Reeves-Hoché M-K, Denis M, (2010) Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. The Lancet 375: 41-8.
35. Plennevaux E, Blatter M, Cornish MJ, Go K, Kirby D, et al. (2011) Influenza A (H1N1) 2009 two-dose immunization of US children: an observer-blinded, randomized, placebo-controlled trial. Vaccine 2011 29: 1569-75.
36. Greenberg ME, Lai MH, Hartel GF, Wichems CH, Gittleson C, et al. (2009) Response to monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 361: 2405-2413.
37. Zhu F-C, Wang H, Fang H-H, Yang JG, Lin XJ, et al. (2009) A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 361: 2414-2423.
38. Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, et al. (2009) Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 361: 2424-2435.
39. Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, et al. (2010) Immunogenicity and safety in adults of one dose of influenza A H1N1 v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 28: 1740-1745.
40. Jonuleit H, Kühn U, Müller G, Steinbrink K, Paragnik L, et al. (1997) Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 27: 3135-3142.
41. Decker WK, Xing D, Li S, Robinson SN, Yang H, et al. (2006) Double loading of dendritic cell MHC class I and MHC class II with an AML antigen repertoire enhances correlates of T-cell immunity in vitro via amplification of T-cell help. Vaccine 24: 3203-3216.
42. Gulati U, Kumari K, Wu W, Keitel WA, Air GM, (2005) Amount and avidity of serum antibodies against native glycoproteins and denatured virus after repeated influenza whole-virus vaccination. Vaccine 23: 1414-1425.
43. Feng J, Gulati U, Zhang X, Keitel WA, Thompson DM, et al. (2009) Antibody quantity versus quality after influenza vaccination. Vaccine 27: 6358-6362.
44. Stephenson I, Wood JM, Nicholson KG, Charlett A, Zambon MC, (2004) Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res 103: 91-95.
45. Jia N, Wang S-X, Liu Y-X, Zhang P-H, Zuo S-Q, et al. (2008) Increased sensitivity for detecting avian influenza-specific antibodies by a modified hemagglutination inhibition assay using horse erythrocytes. J Virol Methods 153: 43-48.
46. Couch RB, (2008) Seasonal inactivated influenza virus vaccines. Vaccine 265: D5-D9.
47. Centers for Disease Control (2010) Prevention and control of influenza with vaccines. Recommendations of the advisory committee on immunization practices (ACIP), 2010. MMWR 59: 1-47.
48. Miller GL, Stanley WM, (1944) Quantitative aspects of the red blood cell agglutination test for influenza virus. J Exp Med 79: 185-195.
49. Renfrey S, Watts A, (1994) Morphological and biochemical characterization of influenza vaccines commercially available in the United Kingdom. Vaccine 12: 747-752.
50. National Institutes of Health (1977) Clinical studies of influenza vaccines - 1976. J Infect Dis 136 (Sup): S397-S746.
51. Laver WG, Webster RG, (1976) Preparation and immunogenicity of an influenza virus hemagglutinin and neuraminidase subunit vaccine. Virology 69: 511-522.
52. Webster RG, Kasel JA, Couch RB, Laver WG, (1976) Influenza virus subunit vaccines. II. Immunogenicity and original antigenic sin in humans. J Infect Dis 134: 48-58.
53. Webster RG, Glezen WP, Hannoun C, Laver WG, (1977) Potentiation of the immune response to influenza virus subunit vaccines. J Immunol 119: 2073-2077.
54. Frank AL, Webster RG, Glezen WP, Cate TR, (1981) Immunogenicity of influenza A/USSR (H1N1) subunit vaccine in unprimed young adults. J Med Virol 7: 135-142.
55. Wood JM, Gaines-Das RE, Taylor J, Chakraverty P, (1994) Comparison of influenza serological techniques by international collaborative study. Vaccine 12: 167-174.
56. Wood JM, Major D, Heath A, Newman RW, Höschler K, et al. (2012) Reproducibility of serology assays for pandemic influenza H1N1: collaborative study to evaluate a candidate WHO international standard. Vaccine 30: 210-217.